Xianghua Yi

Dr. Xianghua Yi


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
SLShuai Li
Shuai Li
SLShengwu Liu
Shengwu Liu
JDJiehui Deng
Jiehui Deng
EAEsra Akbay
Esra Akbay
JHJosephine Hai
Josephine Hai
KWKwok-Kin Wong
Kwok-Kin Wong
Purpose: Despite the challenge to directly target mutant KRAS due to its high GTP affinity, some agents are under development against downstream signaling pathways, such as MEK inhibitors. However, it remains controversial whether MEK inhibitors can boost current chemotherapy in KRAS-mutant lung tumors in clinic. Considering the genomic heterogeneity among patients with lung cancer, it is valuable to test potential therapeutics in KRAS mutation–driven mouse models. Experimental Design: We first compared the pERK1/2 level in lung cancer samples with different KRAS substitutions and generated a new genetically engineered mouse model whose tumor was driven by KRASG12C, the most common KRAS mutation in lung cancer. Next, we evaluated the efficacy of selumetinib or its combination with chemotherapy, in KRASG12C tumors compared with KRASG12D tumors. Moreover, we generated KRASG12C/p53R270H model to explore the role of a dominant negative p53 mutation detected in patients in responsiveness to MEK inhibition. Results: We determined higher pERK1/2 in KRASG12C lung tumors compared with KRASG12D. Using mouse models, we further identified that KRASG12C tumors are significantly more sensitive to selumetinib compared with KrasG12D tumors. MEK inhibition significantly increased chemotherapeutic efficacy and progression-free survival of KRASG12C mice. Interestingly, p53 co-mutation rendered KRASG12C lung tumors less sensitive to combination treatment with selumetinib and chemotherapy. Conclusions: Our data demonstrate that unique KRAS mutations and concurrent mutations in tumor-suppressor genes are important factors for lung tumor responses to MEK inhibitor. Our preclinical study supports further clinical evaluation of combined MEK inhibition and chemotherapy for lung cancer patients harboring KRASG12C and wild-type p53 status. Clin Cancer Res; 24(19); 4854–64. ©2018 AACR.

1 August 2015
Verified
Journal Article
Closed access
HZHailong Zhu
Hailong Zhu
HQHuali Qin
Huali Qin
ZHZiling Huang
Ziling Huang
SLShuai Li
Shuai Li
XZXuyou Zhu
Xuyou Zhu
XYXianghua Yi
Xianghua Yi

9 August 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
XYXiaoting Yu
Xiaoting Yu
PGPan Gu
Pan Gu
ZHZiling Huang
Ziling Huang
XFXia Fang
Xia Fang
YJYing Jiang
Ying Jiang
XYXianghua Yi
Xianghua Yi
Reduced expression of BMP3 contributes to the development of pulmonary fibrosis and predicts the unfavorable prognosis in IIP patients Reduced expression of BMP3 contributes to the development of pulmonary fibrosis and predicts the unfavorable prognosis in IIP patients

1 October 2020 in Science of The Total Environment
Verified
Journal Article
Closed access
ZHZiling Huang
Ziling Huang
SWSiqi Wang
Siqi Wang
YLYuting Liu
Yuting Liu
LFLichao Fan
Lichao Fan
YZYu Zeng
Yu Zeng
XYXianghua Yi
Xianghua Yi

1 December 2021 in Lung Cancer
Verified
Journal Article
Closed access
QLQian Liu
Qian Liu
MQMeng Qiao
Meng Qiao
ZLZoltan Lohinai
Zoltan Lohinai
SMShiqi Mao
Shiqi Mao
YPYingying Pan
Yingying Pan
FHFred R. Hirsch
Fred R. Hirsch

24 July 2014 in Experimental Lung Research
Verified
Journal Article
Closed access
PDF file
HCHanzhang Chen
Hanzhang Chen
XFXia Fang
Xia Fang
HZHailong Zhu
Hailong Zhu
SLShuai Li
Shuai Li
JHJian He
Jian He
XYXianghua Yi
Xianghua Yi
Objective: Idiopathic interstitial pneumonias (IIPs) are a group of diffuse parenchymal lung diseases of unknown etiology characterized by the presence of various degrees of inflammation and fibrosis. We aimed to screen the differences among IIPs subtypes in the gene level by using the microarray expression profiles of normal lung tissue and IIPs tissue for the key genes associated with early diagnosis and treatment of IIPs. Methods: The gene expression profile of six kinds of IIPs (GSE 32537) subtypes tissue and normal lung tissues were downloaded. The differentially expressed genes (DEGs) in different IIPs subtypes were selected by using the expression profiling. In addition, the screened DEGs were further analyzed by function annotation, pathway analysis, and interaction network analysis to reveal the differences among these subtypes. Results: The gene expression analysis showed that nine genes including SERPINA3, IL1R2, CBS, MGAM, SLCO4A1, S100A12, FPR1, SDR16C5, and MT1X in six subtypes of IIPs were significantly increased. There were significant differences in DEGs among six subtypes of IIPs, and the DEGs of some IIPs subtypes involved in immune, inflammatory response and cell adhesion processes. Moreover, the PPI network analysis indicated that SERPINA3 played an important role in the molecular mechanisms of IIPs. Conclusion: This comprehensive description of altered gene expression in different subtypes of IIPs underscores the complex biological processes characteristic of different subtypes of IIPs and may provide a foundation for future research into this devastating disease.